Select publications

BIG 1-98 Collaborative Group. Letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind Phase III study. Abstract

Coleman RE et al. Intergroup Exemestane Study: 1 year results of the bone sub-protocol. San Antonio Breast Cancer Symposium 2004;Abstract 401.

Coombes RC et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifenupdated survival analysis. San Antonio Breast Cancer Symposium 2004;Abstract 3.

Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen: Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium 2004;Abstract 6.

Howell A, on behalf of the ATAC Trialists’ Group. ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) completed treatment analysis: Anastrozole demonstrates superior efficacy and tolerability compared with tamoxifen. San Antonio Breast Cancer Symposium 2004;Abstract 1.

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Perez EA et al. Effect of letrozole versus placebo on bone mineral density in women completing 5 years (yrs) of adjuvant tamoxifen: NCIC CTG MA.17b. San Antonio Breast Cancer Symposium 2004;Abstract 404.